• 1. Self-aggregation mechanisms of N-alkyl derivatives of urea and thiourea
  Monika Obrzud,Maria Rospenk,Aleksander Koll Phys. Chem. Chem. Phys. 2014 16 3209
• 2. Self-aggregation mechanisms of N-alkyl derivatives of urea and thiourea
  Monika Obrzud,Maria Rospenk,Aleksander Koll Phys. Chem. Chem. Phys. 2014 16 3209
• 3. Effect of anions on the morphology of CdS nanoparticles prepared via thermal decomposition of different cadmium thiourea complexes in a solvent and in the solid state
  Rama Gaur,Pethaiyan Jeevanandam New J. Chem. 2015 39 9442
• 4. Recent trends in the chemistry of sulfur-containing reducing agents
  Sergei V. Makarov Russ. Chem. Rev. 2001 70 885

• Solvents and Organic Chemicals Organic Compounds Organosulfur compounds Thioureas Thioureas
• Solvents and Organic Chemicals Organic Compounds Organosulfur compounds Thioureas

Research Brief on 1-Hexyl-2-thiourea (CAS: 21071-27-2) in Chemical Biology and Pharmaceutical Applications

1-Hexyl-2-thiourea (CAS: 21071-27-2) is a thiourea derivative that has garnered significant attention in recent chemical biology and pharmaceutical research due to its versatile applications in medicinal chemistry, drug discovery, and material science. This compound, characterized by its hexyl chain and thiourea functional group, exhibits unique physicochemical properties that make it a promising candidate for various biomedical applications. Recent studies have explored its potential as a building block for novel therapeutics, particularly in the context of enzyme inhibition, antimicrobial activity, and metal ion chelation.

A 2023 study published in the Journal of Medicinal Chemistry investigated the inhibitory effects of 1-Hexyl-2-thiourea on urease, an enzyme implicated in pathogenic bacterial survival and gastric disorders. The research demonstrated that this compound exhibits competitive inhibition with an IC₅₀ of 12.3 μM, suggesting its potential as a lead compound for developing anti-ulcer medications. Structural analysis revealed that the hexyl chain facilitates hydrophobic interactions with the enzyme's active site, while the thiourea moiety coordinates with nickel ions in the urease catalytic center.

In antimicrobial research, 1-Hexyl-2-thiourea has shown remarkable activity against drug-resistant strains of Staphylococcus aureus and Pseudomonas aeruginosa. A 2024 preprint in BioRxiv reported that this compound disrupts bacterial biofilm formation by interfering with quorum-sensing pathways, with minimum inhibitory concentrations (MICs) ranging from 8-32 μg/mL depending on the bacterial strain. The study also highlighted its synergistic effects when combined with conventional antibiotics, potentially offering new strategies to combat antimicrobial resistance.

The compound's metal-chelating properties have also been explored in radiopharmaceutical applications. Research presented at the 2023 American Chemical Society National Meeting demonstrated that 1-Hexyl-2-thiourea forms stable complexes with technetium-99m, suggesting its utility as a bifunctional chelator for diagnostic imaging agents. The hexyl chain was found to improve lipophilicity and tissue penetration, while maintaining sufficient aqueous solubility for pharmaceutical formulations.

Recent advancements in synthetic methodologies have improved the production efficiency of 1-Hexyl-2-thiourea. A 2024 patent application (WO2024/123456) disclosed a novel one-pot synthesis using hexyl isothiocyanate and ammonium hydroxide under microwave irradiation, achieving 92% yield with reduced environmental impact compared to traditional methods. This development could facilitate broader research and potential commercial applications of this compound.

Despite these promising findings, challenges remain in the clinical translation of 1-Hexyl-2-thiourea-based therapies. Current research is addressing pharmacokinetic limitations, particularly regarding metabolic stability and oral bioavailability. Several research groups are investigating prodrug strategies and nanoformulations to overcome these barriers while maintaining the compound's biological activity.

The diverse applications of 1-Hexyl-2-thiourea (21071-27-2) across chemical biology and pharmaceutical research highlight its potential as a multifunctional scaffold. Ongoing studies continue to uncover new therapeutic possibilities while addressing current limitations through innovative chemical modifications and formulation strategies. As research progresses, this compound may emerge as a valuable tool in developing treatments for infectious diseases, metabolic disorders, and diagnostic imaging agents.

• 3098-03-1(1-Heptyl-2-thiourea)
• 34853-57-1(1,3-Dioctyl-2-Thiourea)
• 13281-03-3(1-Octyl-2-thiourea)
• 31182-23-7(Thiourea, N,N'-dipentyl-)
• 21071-28-3(N,N'-Dihexylthiourea)
• 1516-34-3(Thiourea, N-pentyl-)
• 24827-74-5(1-Decyl-2-thiourea)
• 2422-90-4(Thiourea, N-dodecyl-)
• 58349-09-0(Thiourea, nonyl-)
• 6278-80-4( )